Previous 10 | Next 10 |
Genocea Biosciences (GNCA): Q4 GAAP EPS of -$0.18 beats by $0.03.As of December 31, 2020, cash and cash equivalents were $79.8 million compared to $40.1 million as of December 31, 2019.Press Release For further details see: Genocea Biosciences EPS beats by $0.03
GEN-011 and GEN-009 clinical trials continue to advance ATLAS TM stimulatory antigen and inhibitory antigen (Inhibigen TM ) identification profiled in Cancer Discovery Announcing SARS-CoV-2 T cell antigen discovery pr...
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2020 financial results and corporate update conference call and live audio webcas...
Genocea Biosciences (GNCA) soars 47% premarket after highlighting the advantages of neoantigen identification with the ATLAS platform in a journal Cancer Discovery.The publication shows that ATLAS zeroes in on tumor mutations that are either neoantigens that activate ...
Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigens of anti-tumor T cell responses and excluding Inhibigens™, or neoantigens of pro-tumor T cell responses CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Genoce...
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a firesid...
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview ...
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview ...
Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies GEN-011, a n eoantigen-targeted p eripheral T cell (“NPT”)...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
Genocea Biosciences Inc. Company Name:
GNCA Stock Symbol:
NASDAQ Market:
Genocea Biosciences Inc Ordinary Shares (GNCA) is expected to report for Q4 2022